Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
Bioiberica has followed a vertical integration strategy in the last three years towards the development and sale of finished products. All products undergo scientific and clinical development and have their own marketing strategy to support sales in each country.
Bioiberica has revamped its corporate website to make it more up to date, operative and interesting for different audiences.